Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) secured approval from the U.S. Food and Drug Administration for Pasatru (garetosmab-grts), a novel therapy for adults battling fibrodysplasia ossificans progressiva (FOP).

The regulatory nod allows the drug to tackle the formation of new heterotopic ossification (HO) lesions and reduce clinician-assessed flare-ups associated with this ultra-rare condition.

Understanding FOP And Treatment Administration

FOP progressively infiltrates muscles, ligaments, and tendons with abnormal bone growth. This severe dysfunction hinders essential actions like eating, speaking, and breathing.

With approximately 900 diagnosed cases worldwide, patients face a median survival age of 56 and often require wheelchairs by age 30.

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN

Other newsrooms on this story

Related reading

Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder

FDA approves Regeneron’s drug for ultra-rare disease that turns tissue to bone

Regeneron drug for disease that causes dangerous bone growth earns FDA approval

FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans…

FDA Approves Activin Signaling Inhibitor for Bone Disorder

Regeneron to challenge Ipsen as FDA clears bone disease drug